Tags

Type your tag names separated by a space and hit enter

A randomized, placebo-controlled trial of coenzyme Q10 and remacemide in Huntington's disease.
Neurology. 2001 Aug 14; 57(3):397-404.Neur

Abstract

OBJECTIVES

To determine whether chronic treatment with coenzyme Q10 or remacemide hydrochloride slows the functional decline of early Huntington's disease (HD).

METHODS

The authors conducted a multicenter, parallel group, double-blind, 2 x 2 factorial, randomized clinical trial. Research participants with early HD (n = 347) were randomized to receive coenzyme Q10 300 mg twice daily, remacemide hydrochloride 200 mg three times daily, both, or neither treatment, and were evaluated every 4 to 5 months for a total of 30 months on assigned treatment. The prespecified primary measure of efficacy was the change in total functional capacity (TFC) between baseline and 30 months. Safety measures included the frequency of clinical adverse events.

RESULTS

Neither intervention significantly altered the decline in TFC. Patients treated with coenzyme Q10 showed a trend toward slowing in TFC decline (13%) over 30 months (2.40- versus 2.74-point decline, p = 0.15), as well as beneficial trends in some secondary measures. There was increased frequency of nausea, vomiting, and dizziness with remacemide and increased frequency of stomach upset with coenzyme Q10.

CONCLUSIONS

Neither remacemide nor coenzyme Q10, at the dosages studied, produced significant slowing in functional decline in early HD.

Authors

No affiliation info available

Pub Type(s)

Clinical Trial
Journal Article
Randomized Controlled Trial
Research Support, Non-U.S. Gov't
Research Support, U.S. Gov't, P.H.S.

Language

eng

PubMed ID

11502903

Citation

Huntington Study Group. "A Randomized, Placebo-controlled Trial of Coenzyme Q10 and Remacemide in Huntington's Disease." Neurology, vol. 57, no. 3, 2001, pp. 397-404.
Huntington Study Group. A randomized, placebo-controlled trial of coenzyme Q10 and remacemide in Huntington's disease. Neurology. 2001;57(3):397-404.
Huntington Study Group. (2001). A randomized, placebo-controlled trial of coenzyme Q10 and remacemide in Huntington's disease. Neurology, 57(3), 397-404.
Huntington Study Group. A Randomized, Placebo-controlled Trial of Coenzyme Q10 and Remacemide in Huntington's Disease. Neurology. 2001 Aug 14;57(3):397-404. PubMed PMID: 11502903.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - A randomized, placebo-controlled trial of coenzyme Q10 and remacemide in Huntington's disease. A1 - ,, PY - 2001/8/15/pubmed PY - 2002/1/5/medline PY - 2001/8/15/entrez SP - 397 EP - 404 JF - Neurology JO - Neurology VL - 57 IS - 3 N2 - OBJECTIVES: To determine whether chronic treatment with coenzyme Q10 or remacemide hydrochloride slows the functional decline of early Huntington's disease (HD). METHODS: The authors conducted a multicenter, parallel group, double-blind, 2 x 2 factorial, randomized clinical trial. Research participants with early HD (n = 347) were randomized to receive coenzyme Q10 300 mg twice daily, remacemide hydrochloride 200 mg three times daily, both, or neither treatment, and were evaluated every 4 to 5 months for a total of 30 months on assigned treatment. The prespecified primary measure of efficacy was the change in total functional capacity (TFC) between baseline and 30 months. Safety measures included the frequency of clinical adverse events. RESULTS: Neither intervention significantly altered the decline in TFC. Patients treated with coenzyme Q10 showed a trend toward slowing in TFC decline (13%) over 30 months (2.40- versus 2.74-point decline, p = 0.15), as well as beneficial trends in some secondary measures. There was increased frequency of nausea, vomiting, and dizziness with remacemide and increased frequency of stomach upset with coenzyme Q10. CONCLUSIONS: Neither remacemide nor coenzyme Q10, at the dosages studied, produced significant slowing in functional decline in early HD. SN - 0028-3878 UR - https://www.unboundmedicine.com/medline/citation/11502903/A_randomized_placebo_controlled_trial_of_coenzyme_Q10_and_remacemide_in_Huntington's_disease_ L2 - http://www.neurology.org/cgi/pmidlookup?view=long&pmid=11502903 DB - PRIME DP - Unbound Medicine ER -